

# Raoul Poupon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3407999/publications.pdf>

Version: 2024-02-01

95  
papers

18,369  
citations

12597

71  
h-index

46524

93  
g-index

96  
all docs

96  
docs citations

96  
times ranked

12308  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary biliary cirrhosis. <i>Hepatology</i> , 2009, 50, 291-308.	3.6	1,020
2	A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 1991, 324, 1548-1554.	13.9	709
3	Controlled Attenuation Parameter (CAP): A Novel VCTE <sub>2</sub> Guided Ultrasonic Attenuation Measurement for the Evaluation of Hepatic Steatosis: Preliminary Study and Validation in a Cohort of Patients with Chronic Liver Disease from Various Causes. <i>Ultrasound in Medicine and Biology</i> , 2010, 36, 1825-1835.	0.7	683
4	Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. <i>Hepatology</i> , 2004, 40, 652-659.	3.6	681
5	Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. <i>Gut</i> , 2013, 62, 531-539.	6.1	663
6	Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy. <i>Hepatology</i> , 1998, 28, 296-301.	3.6	633
7	Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: A second type of "autoimmune" hepatitis. <i>Hepatology</i> , 1987, 7, 1333-1339.	3.6	571
8	Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2008, 48, 871-877.	3.6	552
9	Ursodiol for the Long-Term Treatment of Primary Biliary Cirrhosis. <i>New England Journal of Medicine</i> , 1994, 330, 1342-1347.	13.9	467
10	Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. <i>Liver International</i> , 2009, 29, 242-247.	1.9	432
11	Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. <i>Hepatology</i> , 2002, 35, 1010-1021.	3.6	416
12	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , 2015, 62, S25-S37.	1.8	406
13	Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. <i>Hepatology</i> , 2006, 43, 1118-1124.	3.6	401
14	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2018, 378, 2171-2181.	13.9	383
15	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
16	Determinants of outcome of compensated hepatitis C virus-related cirrhosis. <i>Hepatology</i> , 1998, 27, 1435-1440.	3.6	359
17	Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. <i>Journal of Hepatology</i> , 2011, 55, 1361-1367.	1.8	353
18	Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. <i>Hepatology</i> , 1990, 11, 12-15.	3.6	313

#	ARTICLE	IF	CITATIONS
19	MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. <i>Gastroenterology</i> , 2001, 120, 1459-1467.	0.6	309
20	Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. <i>Hepatology</i> , 2005, 41, 307-314.	3.6	308
21	A Randomized Controlled Study of Propranolol for Prevention of Recurrent Gastrointestinal Bleeding in Patients with Cirrhosis: A Final Report. <i>Hepatology</i> , 1984, 4, 355-358.	3.6	292
22	Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. <i>Journal of Hepatology</i> , 2001, 34, 428-434.	1.8	289
23	Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. <i>Hepatology</i> , 2012, 56, 198-208.	3.6	277
24	ABCB4 gene mutation-associated cholelithiasis in adults. <i>Gastroenterology</i> , 2003, 125, 452-459.	0.6	267
25	The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. <i>Hepatology</i> , 2000, 32, 1196-1199.	3.6	265
26	Primary biliary cirrhosis: A 2010 update. <i>Journal of Hepatology</i> , 2010, 52, 745-758.	1.8	251
27	Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2007, 46, 658-665.	3.6	244
28	Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: A prospective study of 935 patients. <i>Journal of Hepatology</i> , 2007, 46, 628-634.	1.8	227
29	Chronic liver injury during obstructive sleep apnea. <i>Hepatology</i> , 2005, 41, 1290-1296.	3.6	221
30	The Myofibroblastic Conversion of Peribiliary Fibrogenic Cells Distinct from Hepatic Stellate Cells Is Stimulated by Platelet-Derived Growth Factor During Liver Fibrogenesis. <i>Laboratory Investigation</i> , 2003, 83, 163-173.	1.7	206
31	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
32	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 39, 12-16.	1.8	199
33	Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2010, 53, 162-169.	1.8	197
34	Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis. <i>American Journal of Pathology</i> , 1999, 155, 1065-1073.	1.9	189
35	Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. <i>Hepatology</i> , 1999, 29, 1668-1671.	3.6	184
36	Long term outcome and response to therapy of primary biliary cirrhosis-associated autoimmune hepatitis overlap syndrome. <i>Journal of Hepatology</i> , 2006, 44, 400-406.	1.8	181

#	ARTICLE	IF	CITATIONS
37	Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: An overview of their mechanisms of action. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, S3-S12.	0.7	177
38	Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. <i>Hepatology</i> , 2005, 41, 82-87.	3.6	169
39	Ursodeoxycholic acid for primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 1990, 11, 120-123.	1.8	164
40	Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. <i>Hepatology</i> , 1999, 29, 1007-1012.	3.6	162
41	Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. <i>Hepatology</i> , 2006, 44, 85-90.	3.6	153
42	Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor- $\alpha$ production by monocytes. <i>Hepatology</i> , 1992, 16, 719-723.	3.6	139
43	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
44	PDGF-Mediated Chemoattraction of Hepatic Stellate Cells by Bile Duct Segments in Cholestatic Liver Injury. <i>Laboratory Investigation</i> , 2000, 80, 697-707.	1.7	131
45	Non-organ specific autoantibodies associated with chronic C virus hepatitis. <i>Journal of Hepatology</i> , 1993, 18, 359-364.	1.8	127
46	A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. <i>Hepatology</i> , 2007, 46, 528-534.	3.6	123
47	Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. <i>Liver International</i> , 2009, 29, 1431-1438.	1.9	121
48	Serum bile acids in primary biliary cirrhosis: Effect of ursodeoxycholic acid therapy. <i>Hepatology</i> , 1993, 17, 599-604.	3.6	118
49	Quality of life in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2004, 40, 489-494.	3.6	118
50	Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 636-641.	2.4	118
51	Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: Results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. <i>Hepatology</i> , 1990, 12, 1413-1419.	3.6	115
52	Genetic factors of susceptibility and of severity in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2008, 49, 1038-1045.	1.8	115
53	Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of $\alpha$ -interferon therapy. <i>Journal of Hepatology</i> , 1995, 22, 22-26.	1.8	113
54	Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib. <i>International Journal of Cancer</i> , 2006, 119, 2557-2566.	2.3	113

#	ARTICLE	IF	CITATIONS
55	Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. <i>Hepatology</i> , 1985, 5, 722-727.	3.6	107
56	Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse. <i>Gastroenterology</i> , 1992, 103, 617-621.	0.6	107
57	Genotype-phenotype relationships in the low-phospholipid-associated cholelithiasis syndrome: A study of 156 consecutive patients. <i>Hepatology</i> , 2013, 58, 1105-1110.	3.6	105
58	Factors predictive of the response to interferon in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 1994, 21, 12-17.	1.8	98
59	Hepatic Stellate Cell Proliferation is an Early Platelet-Derived Growth Factor-Mediated Cellular Event in Rat Cholestatic Liver Injury. <i>Laboratory Investigation</i> , 2001, 81, 1709-1716.	1.7	95
60	Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. <i>Journal of Hepatology</i> , 2000, 32, 447-452.	1.8	93
61	Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis. <i>Hepatology</i> , 2017, 65, 152-163.	3.6	93
62	Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. <i>Journal of Hepatology</i> , 1994, 20, 388-393.	1.8	89
63	Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 3497.	1.4	87
64	Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. <i>Journal of Hepatology</i> , 2015, 63, 1449-1458.	1.8	84
65	Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. <i>Hepatology</i> , 2009, 50, 528-537.	3.6	83
66	Effect of The Interaction Between Steatosis and Alcohol Intake on Liver Fibrosis Progression in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2002, 97, 1807-1812.	0.2	82
67	Amoxicillin-clavulanic acid therapy of spontaneous bacterial peritonitis: A prospective study of twenty-seven cases in cirrhotic patients. <i>Hepatology</i> , 1990, 11, 360-364.	3.6	80
68	Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study. <i>Hepatology</i> , 2001, 34, 573-577.	3.6	78
69	Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1999, 30, 408-412.	1.8	77
70	Fetal microchimerism in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000, 33, 696-700.	1.8	77
71	Hepatocyte Growth Factor and c-Met Inhibition by Hepatic Cell Hypoxia. <i>American Journal of Pathology</i> , 2002, 160, 613-620.	1.9	76
72	Liver alkaline phosphatase: A missing link between cholestasis and biliary inflammation. <i>Hepatology</i> , 2015, 61, 2080-2090.	3.6	76

#	ARTICLE	IF	CITATIONS
73	Aspects of liver pathology in adult patients with MDR3/ABCB4 gene mutations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 291-298.	1.4	69
74	Autoimmune overlapping syndromes. <i>Clinics in Liver Disease</i> , 2003, 7, 865-878.	1.0	64
75	Shaping macrophages function and innate immunity by bile acids: Mechanisms and implication in cholestatic liver diseases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 550-556.	0.7	63
76	Bile acids modulate the interferon signalling pathway. <i>Hepatology</i> , 1999, 29, 1840-1847.	3.6	53
77	Cholestasis induces major histocompatibility complex class I expression in hepatocytes. <i>Gastroenterology</i> , 1992, 102, 1371-1377.	0.6	48
78	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	1.8	47
79	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 521-528.	0.7	40
80	Effect of cholestasis and bile acids on interferon-induced 2'5'-adenylate synthetase and NK cell activities. <i>Gastroenterology</i> , 1995, 108, 1192-1198.	0.6	38
81	Combined features of low phospholipid-associated cholelithiasis and progressive familial intrahepatic cholestasis 3. <i>Liver International</i> , 2010, 30, 327-331.	1.9	35
82	Intrahepatic cholestasis of pregnancy: from bedside to bench to bedside. <i>Liver International</i> , 2005, 25, 467-468.	1.9	28
83	Changing nomenclature for PBC: from "cirrhosis" to "cholangitis". <i>Gut</i> , 2015, 64, 1671-1672.	6.1	28
84	Immune response to lipopolysaccharide in primary biliary cirrhosis and autoimmune diseases. <i>Journal of Autoimmunity</i> , 2004, 22, 153-158.	3.0	27
85	Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities. <i>JHEP Reports</i> , 2021, 3, 100201.	2.6	24
86	New treatments/targets for primary biliary cholangitis. <i>JHEP Reports</i> , 2019, 1, 203-213.	2.6	17
87	ASBT inhibitors in cholangiopathies " Good for mice, good for men?. <i>Journal of Hepatology</i> , 2016, 64, 537-538.	1.8	13
88	Inhibition of procoagulant activity of human monocytes by chenodeoxycholic acid: Involvement of protein kinase C. <i>Hepatology</i> , 1994, 19, 1164-1170.	3.6	12
89	Differential effects of chenodeoxycholic and ursodeoxycholic acids on expression of procoagulant activity by human monocytes. <i>Journal of Hepatology</i> , 1994, 20, 466-472.	1.8	12
90	Effects of bile acids on the humoral immune response A mechanistic approach. <i>Life Sciences</i> , 2001, 69, 2337-2348.	2.0	12

#	ARTICLE	IF	CITATIONS
91	Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis. <i>Gut</i> , 2019, 68, 1902-1903.	6.1	10
92	Fenofibrate-induced massive regression of multiple inflammatory hepatocellular adenoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, e1-e3.	0.7	6
93	Serum proteomic signatures as biomarkers of primary biliary cirrhosis diagnosis and prognosis. <i>Annales De Biologie Clinique</i> , 2016, 74, 607-612.	0.2	4
94	Treatment of primary biliary cirrhosis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 11-25.	0.5	0
95	Therapeutics Highlights from ILC 2018, the EASL annual congress. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 294-295.	0.7	0